Drugs Made In America Acquisition Corp
DMAAU10.460USD
-0.120-1.13%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
0.00Marktkapitalisierung
--KGV TTM
mehr Informationen über Drugs Made In America Acquisition Corp Unternehmen
Drugs Made In America Acquisition Corp. is a blank check company. The Company is incorporated as an exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. Its efforts to identify a prospective target business will not be limited to a particular industry or geographic region although it intends to focus its search for business combination targets in the pharmaceutical industry.
Unternehmensinformationen
BörsenkürzelDMAAU
Name des UnternehmensDrugs Made In America Acquisition Corp
IPO-datumJan 28, 2025
CEOMs. Lynn Stockwell
Anzahl der mitarbeiter- -
WertpapierartUnit
Geschäftsjahresende- -
Addresse1 East Broward Boulevard
StadtFT LAUDERDALE
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl33301
Telefon19548703099
Website
BörsenkürzelDMAAU
IPO-datumJan 28, 2025
CEOMs. Lynn Stockwell
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director Nominee
Independent Director Nominee
--
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn C. Worman
Mr. Glenn C. Worman
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director Nominee
Independent Director Nominee
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director Nominee
Independent Director Nominee
--
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn C. Worman
Mr. Glenn C. Worman
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director Nominee
Independent Director Nominee
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Drugs Made In America Acquisition LLC
17.88%
Heights Capital Management, Inc.
2.77%
Boothbay Fund Management, LLC
2.58%
Westchester Capital Management, LLC
2.13%
RiverNorth Capital Management LLC
1.79%
Other
72.84%
Aktionäre
Aktionäre
Anteil
Drugs Made In America Acquisition LLC
17.88%
Heights Capital Management, Inc.
2.77%
Boothbay Fund Management, LLC
2.58%
Westchester Capital Management, LLC
2.13%
RiverNorth Capital Management LLC
1.79%
Other
72.84%
Aktionärstypen
Aktionäre
Anteil
Corporation
17.88%
Investment Advisor/Hedge Fund
7.68%
Hedge Fund
3.54%
Investment Advisor
2.85%
Research Firm
0.03%
Other
68.02%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
20
7.49M
31.98%
+7.31M
2025Q1
20
7.60M
32.43%
+7.41M
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Drugs Made In America Acquisition LLC
4.19M
17.88%
+4.19M
--
Feb 18, 2025
Heights Capital Management, Inc.
650.00K
2.77%
+650.00K
--
Mar 31, 2025
Boothbay Fund Management, LLC
603.75K
2.58%
+603.75K
--
Mar 31, 2025
Westchester Capital Management, LLC
500.00K
2.13%
+500.00K
--
Mar 31, 2025
RiverNorth Capital Management LLC
420.50K
1.79%
+418.00K
+16719.92%
Mar 31, 2025
Context Capital Management LLC
250.00K
1.07%
+250.00K
--
Mar 31, 2025
Schonfeld Strategic Advisors LLC
234.83K
1%
+234.83K
--
Mar 31, 2025
Bulldog Investors, LLP
130.26K
0.56%
+130.26K
--
Mar 31, 2025
Wolverine Asset Management, LLC
130.00K
0.55%
+130.00K
--
Mar 31, 2025
Verition Fund Management LLC
100.00K
0.43%
+100.00K
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
SPAC and New Issue ETF
2.39%
RiverNorth Enhanced Pre-Merger SPAC ETF
0.51%
CrossingBridge Pre-Merger SPAC ETF
0%
SPAC and New Issue ETF
Anteil2.39%
RiverNorth Enhanced Pre-Merger SPAC ETF
Anteil0.51%
CrossingBridge Pre-Merger SPAC ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
